IN2012DN00767A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00767A IN2012DN00767A IN767DEN2012A IN2012DN00767A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A IN 767DEN2012 A IN767DEN2012 A IN 767DEN2012A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A
- Authority
- IN
- India
- Prior art keywords
- therapy
- initiation
- tools
- response
- serum
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 230000000977 initiatory effect Effects 0.000 abstract 2
- 102000011690 Adiponectin Human genes 0.000 abstract 1
- 108010076365 Adiponectin Proteins 0.000 abstract 1
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 abstract 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 abstract 1
- 102000057248 Lipoprotein(a) Human genes 0.000 abstract 1
- 108010033266 Lipoprotein(a) Proteins 0.000 abstract 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22899409P | 2009-07-28 | 2009-07-28 | |
| PCT/US2010/041714 WO2011014349A1 (en) | 2009-07-28 | 2010-07-12 | Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00767A true IN2012DN00767A (enExample) | 2015-06-26 |
Family
ID=43529642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN767DEN2012 IN2012DN00767A (enExample) | 2009-07-28 | 2010-07-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120178100A1 (enExample) |
| EP (1) | EP2460007A4 (enExample) |
| CN (1) | CN102576015B (enExample) |
| AU (1) | AU2010276665A1 (enExample) |
| CA (1) | CA2769462A1 (enExample) |
| IN (1) | IN2012DN00767A (enExample) |
| WO (1) | WO2011014349A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012228365A1 (en) | 2011-03-11 | 2013-09-19 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Molecules and methods for inhibition and detection of proteins |
| RU2014125071A (ru) * | 2011-11-21 | 2015-12-27 | Новартис Аг | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa |
| FR3010188B1 (fr) * | 2013-09-05 | 2017-11-24 | Univ Joseph Fourier - Grenoble 1 | Procede theragnostique pour le traitement des rhumatismes inflammatoires chroniques |
| ES3041639T3 (en) * | 2015-09-29 | 2025-11-13 | Univ California | Biomarkers and methods for assessing psoriatic arthritis disease activity |
| JP6751157B2 (ja) * | 2016-05-12 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 疾患を治療するために標的へ向けられた薬物の効力を予測するためのシステム |
| CN109580759A (zh) * | 2017-09-28 | 2019-04-05 | 成都飞机工业（集团）有限责任公司 | 一种四极质谱计 |
| US11232344B2 (en) | 2017-10-31 | 2022-01-25 | General Electric Company | Multi-task feature selection neural networks |
| US12089930B2 (en) | 2018-03-05 | 2024-09-17 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
| US20220064278A1 (en) * | 2019-01-23 | 2022-03-03 | Janssen Biotech, Inc. | Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis |
| CN114518416B (zh) * | 2020-11-20 | 2024-05-24 | 上海交通大学医学院附属瑞金医院 | 一种判断银屑病对il-17a抗体应答反应及其复发的标志物 |
| US20250285762A1 (en) * | 2020-12-18 | 2025-09-11 | Nightingale Health Oyj | Method for determining whether a subject is at risk of developing a musculoskeletal and/or connective tissue disease |
| CA3208411A1 (en) * | 2021-02-25 | 2022-09-01 | George C. Lee | Patient response-based biomarker topology quantification and assessment for multiple tissue types |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002048310A2 (en) * | 2000-12-15 | 2002-06-20 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
| WO2007123976A2 (en) * | 2006-04-18 | 2007-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody profiling for determination of patient responsiveness |
| DK2571532T3 (en) * | 2010-05-14 | 2017-08-28 | Abbvie Inc | IL-1 BINDING PROTEINS |
-
2010
- 2010-07-12 IN IN767DEN2012 patent/IN2012DN00767A/en unknown
- 2010-07-12 AU AU2010276665A patent/AU2010276665A1/en not_active Abandoned
- 2010-07-12 US US13/386,998 patent/US20120178100A1/en not_active Abandoned
- 2010-07-12 CA CA2769462A patent/CA2769462A1/en not_active Abandoned
- 2010-07-12 WO PCT/US2010/041714 patent/WO2011014349A1/en not_active Ceased
- 2010-07-12 CN CN201080044717.6A patent/CN102576015B/zh not_active Expired - Fee Related
- 2010-07-12 EP EP10804876.0A patent/EP2460007A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769462A1 (en) | 2011-02-03 |
| CN102576015A (zh) | 2012-07-11 |
| WO2011014349A1 (en) | 2011-02-03 |
| US20120178100A1 (en) | 2012-07-12 |
| CN102576015B (zh) | 2014-09-10 |
| AU2010276665A1 (en) | 2012-02-23 |
| EP2460007A4 (en) | 2013-06-19 |
| EP2460007A1 (en) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00767A (enExample) | ||
| WO2019213282A8 (en) | Biomarkers for evaluating car-t cells to predict clinical outcome | |
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BR112015025407A2 (pt) | método e dispositivo para testar um transformador | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| MX2017010569A (es) | Dispositivo, plataforma y ensayo para evaluacion de celulas. | |
| BR112018003300A2 (pt) | sistemas e métodos para determinar informação relacionada a uma ordem atual com base em ordens históricas | |
| BR112017023188A2 (pt) | plataforma para descoberta e análise de agentes terapêuticos | |
| BR112015004631A2 (pt) | marcadores genéticos de resistência à mastite | |
| BR112015029852A2 (pt) | método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9 | |
| BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
| BR112014018717A8 (pt) | Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b | |
| BR112013025287A2 (pt) | ensaios com receptores de esteroide para detectar células tumorais | |
| BR112021021574A2 (pt) | Método para identificar uma abordagem reprodutiva em um indivíduo que sofre de uma varicocele | |
| UA109274U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA128823U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA108612U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA130515U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA82147U (ru) | Способ прогнозирования риска возникновения ишемического инсульта | |
| UA108259U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA108281U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA95627U (uk) | Спосіб прогнозування зрощення перелому | |
| UA110963U (uk) | Спосіб діагностики розвитку остеопорозу | |
| UA108296U (uk) | Спосіб прогнозування розвитку остеопорозу |